Amy E. DeZern

Johns Hopkins University — United States

Medicine · Health Sciences

57h-index10.6kcitations496works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(304), Myeloproliferative Neoplasms: Diagnosis and Treatment(138), Hematopoietic Stem Cell Transplantation(90), Chronic Myeloid Leukemia Treatments(83), Acute Lymphoblastic Leukemia research(72)

Publications496 total

DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study
Leukemia·2025· 2 cited
A proposed path to explaining the unexplained anemia of aging
The Journals of Gerontology Series A·2025Open Access
Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database
Blood·2025Open Access
A multi-site break through cancer pilot study testing the feasibility and safety of therapeutic intervention for patients with high-risk clonal cytopenia of undetermined significance (CCUS)
Blood·2025
Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms
Blood·2025Open Access
DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors
Blood·2025· 1 citedOpen Access
The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome
Blood·2025
Personalized Desensitization for DSAs in Allogeneic Blood or Marrow Transplantation: Impact on Graft Outcomes and Access to Transplant
Blood·2025
Evaluating large language models in real-world hematologic clinical decision-making: Performance, limitations, and clinical implications
Blood·2025
5-azacytidine treatment reshapes clonal structure and alters mutation-dependent splicing in MDS patients
Blood·2025Open Access
Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques
Blood·2025Open Access
Artificial intelligence‑driven virtual tumor board enhances precision care in myelodysplastic syndromes (MDS)
Blood·2025
Clinical, genetic, and pathologic differences across race, ethnicity, and sex in patients with MDS and precursor conditions from the national MDS natural history study
Blood·2025Open Access
Artificial intelligence-based diagnosis of myelodysplastic syndromes/neoplasms using bone marrow
Blood·2025Open Access
Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database
Blood·2025Open Access
Exposure to agent orange and risk of myelodysplastic syndromes
Blood·2025Open Access
Wide variability and inconsistency in reporting of results of Myelodysplastic Syndromes/neoplasms (MDS) clinical trials: An icMDS systematic review of published manuscripts
Blood·2025Open Access
2003 – MOLECULAR DISSECTION OF AGING CLARIFIES THE IMPACT OF MDS GENETICS AND THERAPY
Experimental Hematology·2025
TEMPORARY REMOVAL: Personalized Desensitization for Donor-Specific Anti-HLA Antibodies in Allogeneic Blood or Marrow Transplantation
Transplantation and Cellular Therapy·2025
Long-Term Follow-Up of the Baltimore Experience with Hematopoietic Cell Transplantation for Severe Aplastic Anemia Using Post-Transplantation Cyclophosphamide
Transplantation and Cellular Therapy·2025
page 1 of 25Next →

Frequent Co-authors

Guillermo Garcia‐Manero(17), Rami S. Komrokji(15), Mikkael A. Sekeres(14), David P. Steensma(12), Gail J. Roboz(12), Robert A. Brodsky(12), Richard J. Jones(12), B. Douglas Smith(10), Leo Luznik(10), Alan F. List(9), Hagop M. Kantarjian(9), Ivana Gojo(9), Mark J. Levis(9), Ephraim J. Fuchs(9), Douglas E. Gladstone(8), Ivan Borrello(8), Lode J. Swinnen(8), Richard F. Ambinder(8), Pierre Fenaux(7), Amer M. Zeidan(7)